Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

9.820 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,298
Open 9.820
Bid (Size) 9.780 (7)
Ask (Size) 9.900 (6)
Prev. Close 9.820
Today's Range 9.820 - 9.820
52wk Range 6.500 - 21.66
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
Via Investor Brand Network
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
From Cybin Inc.
Via Business Wire

Performance

YTD
-35.39%
-35.39%
1 Month
-5.67%
-5.67%
3 Month
-3.07%
-3.07%
6 Month
-26.14%
-26.14%
1 Year
-46.67%
-46.67%

More News

Read More
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present Key 12-Month Data and Phase 3 Program Insights for CYB003 in Upcoming Webcast
Via Investor Brand Network
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
From Cybin Inc.
Via Business Wire
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Via Benzinga
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Begins Phase 3 Trials of CYB003 for Depression, Building on Promising Phase 2 Results
Via Investor Brand Network
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Present Advancements in Mental Health Treatment at Milken Institute Summit
Via Investor Brand Network
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
From Cybin Inc.
Via Business Wire
BioMedNewsBreaks — Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Granted Patent for Lead Candidates in CYB005 Program
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
From Cybin Inc.
Via Business Wire
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat
Via Investor Brand Network
Exposures Product Safety
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Strengthens Its Clinical Development Team
Via Investor Brand Network
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Chief Medical Officer to Participate in a Panel Discussion at Upcoming Summit
Via Investor Brand Network
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports on Status of Key Clinical Milestones
Via Investor Brand Network
Cybin Provides Corporate Update on Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Completes 38-for-1 Share Consolidation
Via Investor Brand Network
Cybin Announces Completion of Previously Announced Share Consolidation
From Cybin Inc.
Via Business Wire
Leadership Shake-Ups In Cannabis And Psychedelics: Maryland's Cannabis Chief Resigns, Costly Legal Battle In MA Drags On & More
Via Benzinga
Topics Cannabis
Exposures Cannabis
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Via Investor Brand Network
Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.